In focus · trending topic

skin microbiome

2 stories · following the connections

MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis

By Nasdaq OMXAug 21, 2017, 10:00 AM UTC

MatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis

By Nasdaq OMXFeb 22, 2017, 10:39 PM UTC